Alkermes plc (ALKS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
$45.37+0.27%
Close 2026-10-29 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-10-29
Research Workspace
Put ALKS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is accelerating — up about 11% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 21%.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — the market is pricing in about 26% growth a year, above the roughly 13% analysts expect, leaving little room for error.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskALKS rests on strong recent performance, with revenue growth slowing slightly from 28% to 27%. The latest quarter beat, supporting its sleep portfolio and alixorexton development. ALKS trades at 25× P/E versus a 16× peer median. The market prices in more growth than our forecast. A 32% next-quarter miss probability threatens this case. The orexin programs also face competition from Takeda and Lilly. Peer multiples imply a price about 26% below where it trades. Our read remains intact, and this read is provisional.
Trailing returns as of 2026-10-29. ALKS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 20 analysts currently covering ALKS (as of Oct 2026).
Based on 5 Wall Street analysts offering 12-month price targets for ALKS in the last 4 months.
Continue this research
Compare ALKS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ALKS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put ALKS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Integrate Avadel acquisition and expand sleep medicine portfolio
Presentation supports integration of Avadel acquisition.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $45.37
The last 12 months of price, then the range of analyst 12-month targets from today’s $45.37.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Threatens: Advance orexin 2 receptor agonist clinical programs
Takeda and Lilly pose competitive threats to orexin programs.
Advances: Advance alixorexton clinical development program
Positive trial data supports alixorexton development.
Advances: Advance alixorexton clinical development program
Positive study results enhance alixorexton's clinical development.
Advances: Drive revenue growth across commercial portfolio
Revenue guidance aligns with growth objectives.
Advances: Increase revenue growth
Price target increase indicates confidence in revenue growth.
Advances: Advance LUMRYZ for idiopathic hypersomnia
Positive data supports LUMRYZ for idiopathic hypersomnia.
Advances: Advance LUMRYZ for idiopathic hypersomnia
Positive trial results support LUMRYZ's market potential.
